Benign prostatic hyperplasia. Part 1 - Diagnosis

BMJ

Volumn 336, Issue 7636, 2008, Pages 146-149

  Wilt, Timothy J ^a   N'Dow, James ^b  

^a Center for Chronic Disease Outcomes Research   (United States)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN; FINASTERIDE; PLACEBO;

BLADDER PRESSURE; CANCER RISK; CYSTOSCOPY; DETRUSOR MUSCLE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE COURSE; ECHOGRAPHY; FOLLOW UP; HUMAN; MICTURITION; NOCTURIA; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; URINARY FREQUENCY; URINARY TRACT DISEASE; URINARY URGENCY; URINE INCONTINENCE; UROFLOWMETRY;

ADULT; AGED; HUMANS; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; PHYSICAL EXAMINATION; PROSTATIC HYPERPLASIA; PROSTATISM; RISK FACTORS; URINARY RETENTION; URODYNAMICS;

EID: 38949127212     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39421.685023.AE     Document Type: Review

References (24)

1. Wei JT, Calhoun EA, Jacobsen SJ. Benign prostatic hyperplasia. In: Litwin MS, Saigal CS, eds. Urologic diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Publishing Office, 2007 (pp 43-70). NIH publication no 07-5512.
2. Foley CL, Taylor C, Kirby RS. Counting the cost of treating benign prostatic hyperplasia. BJU Int 2004;93:250-2.
3. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the epic study. Eur Urol 2006;50:1306-15.
4. Kupelian V, Wei JT, O'Leary MP, Kusek JW, Litman HJ, Link CL, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample. The Boston area community health (BACH) survey. Arch Intern Med 2006;166:2381-7.
5. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9.
6. Trueman P, Hood SC, Nayak USL, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed "benign prostatic hyperplasia" and their effect on quality of life in a community-based survey of men in the UK. BJU Int 1999;83:410-5.
7. Platz EA, Smit E, Curhan GC, Nyberg LM, Giovannucci E. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in US men. Urology 2002;59:877-83.
8. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-71.
9. Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the health professionals follow-up study. Urology 2002;59:245-50.
10. Zucchetto A, Tavani A, Dal Maso L, Gallus S, Negri E, Talamini R, et al. History of weight and obesity through life and risk of benign prostatic hyperplasia. Int J Obes (Lond) 2005;29:798-803.
11. McConnell JD, Roehrborn CB, Bautistia OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
12. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals follow-up study. J Urol 1999;162:376-82.
13. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: Risk factors for acute urinary retention. J Urol 1997;158:481-7.
14. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int 2006;97(suppl 2):3-6.
15. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995;332:75-9.
16. Su L, Guess HA, Girman CJ, Jacobsen SJ, Oesterling JE, Panser LA, et al. Adverse effects of medications on urinary symptoms and flow rate: a community-based study. J Clin Epidemiol 1996;49:483-7.
17. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549-57.
18. Brown CT, O'Flynn E, van der Meulen J, Newman S, Mundy AR, Emberton M. The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened? BJU Int 2003;91:30-2.
19. Young JM, Muscatello DJ, Ward JF. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int 2000;85:1037-48.
20. Wilt TJ, Thompson IM. Clinically localised prostate cancer. BMJ 2006;133:1102-6.
21. American Urological Association. Guideline on the management of benign prostatic hyperplasia (BPH). www.auanet.org/guidelines/bph.cfm (updated 2006).
22. European Association of Urology. Guidelines on benign prostatic hyperplasia. www.uroweb.org/fileadmin/user_upload/Guidelines/11%20BPH.pdf (updated 2004).
23. Schafer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodynamics 2002;21:261-74.
24. Sullivan J, Lewis P, Howell S, Williams T, Shepherd AM, Abrams P. Quality control in urodynamics: a review of urodynamic traces from one centre. BJU Int 2003;91:201-7.